Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas | Yang | Aging Pathobiology and Therapeutics

Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas

Li Yang, Xin Xu


In recent years, the tumor microenvironment has become the focus of immunotherapy in patients with lymphoma, especially with increasing age. The programmed death 1 (PD-1) and programmed death 1 ligand (PD[1]L1) signaling pathway is an important mechanism of cancer immunomodulation, and abnormal activation in the tumor microenvironment shows that the PD-1/PD-L1 pathway may take part in the regulation of tumor immune escape. Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that plays a crucial role in the lymphoma cancer microenvironment and has divided roles in both tumor growth and cancer elimination. Thus IL[1]17A is a potential target in cancer immunotherapy. Previous studies have shown that IL-17A up-regulates the expression of PD-L1 in cancers or in autoimmune diseases but whether there is an interaction or relationship between the PD-1/PD-L1 pathway and IL-17A in lymphoma has not yet been fully recognized. The aim of this review is to track the recent progress of the PD-1/PD-L1 pathway and IL-17A in lymphoma. A better understanding of the role of the PD-1/PDL1 pathway and IL-17A in the progression of lymphoma will help provide new therapeutic directions, especially in older patients.

Keywords: PD-1/PD-L1, IL-17A, lymphoma, tumor microenvironment, aging, immunotherapy

Subscribe to receive issue release notifications
and newsletters from journals